One of the companies of GVK BIO’s investor group has been in the news recently. We would like to clarify that the matter is in no way connected with our company, GVK BIO. We are an independent company with a separate set of investors including a private equity partner, and have strong governance and professional management practices.
We are proud that GVK BIO has emerged as a trusted leader in Contract R&D with operational and business facilities in North America, Europe, and in Asia. Through the pandemic, we have been working tirelessly to support our customer needs and to accelerate their R&D. Our seven global sites are now fully operational, and our nearly 2800 employees are focused on driving programs forward, drawing positive customer feedback. We see good tailwinds for the pharmaceutical outsourcing business, and our management team, led by our CEO, is executing on our strategic growth plans for the company in line with the core values that define GVK BIO.
With Best Regards,
Davinder Singh Brar
Chairman, GVK BIO